Sanofi Consumer Healthcare India Ltd Company Analysis

SANOFICONR Sanofi Consumer Healthcare India Ltd is the Indian consumer-health business of the global Sanofi group, focused on over-the-counter medicines and wellness products. Its well-known brands include Allegra for allergy relief, Combiflam for pain relief, Avil and DePURA. The company benefits from established brands, pharmacy distribution and demand for self-care products. Its growth strategy includes relaunching products and strengthening domestic sales, although quality issues or product recalls could affect customer confidence and sales. In Q3 CY2026, revenue from operations rose 12.5% year-on-year to ₹263.1 crore, while net profit increased 21.8% to ₹76.6 crore. Profit before tax grew 22.1% to ₹102.7 crore, showing that earnings grew faster than revenue during the quarter. For the first nine months of 2026, revenue reached approximately ₹728 crore, compared with ₹627.4 crore in the corresponding period of 2025, while net profit increased to ₹213.2 crore from ₹173.6 crore. The results indicate healthy profitability and improving earnings momentum. Sanofi Consumer Healthcare has a relatively asset-light, high-margin business and no significant debt burden, but valuation and liquidity are important considerations. Recent market coverage has reported a P/E around 29x, though the exact multiple changes with the share price and latest earnings. Trading volumes can be low, which may widen bid–ask spreads and make large transactions harder to execute. Future performance will depend on sustained domestic growth, successful product relaunches and export recovery; risks include input-cost inflation, regulatory price controls and product-quality issues. Overall, the company has strong brands, healthy margins and encouraging earnings growth, but investors should compare its valuation with expected future growth and account for low trading liquidity before drawing a conclusion.